Floatz logo

pf-05212384

mCRPC (Metastatic Castration-resistant Prostate Cancer)

Celcuity IncPhase 1/2Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

229 Active assets in the mCRPC (Metastatic Castration-resistant Prostate Cancer) cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
Darolutamide
Bayer
Phase 3BB
Bms-907351
Rana McKay, MD
Phase 3BB

View all 50 →

Same molecule, other indications

pf-05212384 is also rated in:

breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
therapy-related myeloid neoplasmDormant
CCC
Indicative ·
50 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →